Display options
Cite
Gómez-Solís A, Reyes-Esparza J, García-Vázquez F, et al. Immuno-modulator metallo-Peptide reduces inflammatory state in obese zucker fa/fa rats. Int J Biomed Sci. 2014;10(3):172-81
Gómez-Solís, A., Reyes-Esparza, J., García-Vázquez, F., Alvarez-Ayala, E., & Rodríguez-Fragoso, L. (2014). Immuno-modulator metallo-Peptide reduces inflammatory state in obese zucker fa/fa rats. International journal of biomedical science : IJBS, 10(3), 172-81.
Gómez-Solís, Antonieta, et al. "Immuno-modulator metallo-Peptide reduces inflammatory state in obese zucker fa/fa rats." International journal of biomedical science : IJBS vol. 10,3 (2014): 172-81.
Gómez-Solís A, Reyes-Esparza J, García-Vázquez F, Alvarez-Ayala E, Rodríguez-Fragoso L. Immuno-modulator metallo-Peptide reduces inflammatory state in obese zucker fa/fa rats. Int J Biomed Sci. 2014 Sep;10(3):172-81. PMID: 25324698; PMCID: PMC4198424.
Copy Download .nbib Format: NLM
Share it on

Int J Biomed Sci. 2014 Sep;10(3):172-81.

Immuno-modulator metallo-Peptide reduces inflammatory state in obese zucker fa/fa rats.

International journal of biomedical science : IJBS

Antonieta Gómez-Solís, Jorge Reyes-Esparza, Francisco García-Vázquez, Elizabeth Alvarez-Ayala, Lourdes Rodríguez-Fragoso

Affiliations

  1. Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca 62210, Morelos, México;
  2. Instituto Nacional de Pediatría, México city 04530, México.

PMID: 25324698 PMCID: PMC4198424

Abstract

Metabolic syndrome is a prothrombotic and proinflammatory chronic state. In obesity, the adipose tissue secretes various adipokines that take part in a variety of physiological and pathophysiological processes, including immunity and inflammation. Previous studies using a liver damage model treated with the immune-modulator metallo-peptide (IMMP) showed lessening in the degree of inflammation. Therefore, this study was set up to evaluate the anti-inflammatory effect of IMMP in obese Zucker fa/fa rats. We used Zucker-Lepr fa/fa and Zucker-Lean in this protocol. The groups received IMMP 50 ng/kg by i.p., three times per week for 8 weeks. Blood samples were collected by cardiac puncture and the serum was preserved at -80°C until analysis; the liver was excised and preserved in formaldehyde 4%. Analyses were performed to determine cytokine, insulin, glucose, triglyceride and cholesterol levels in serum, and histological analysis was also performed. IMMP treatment of obese rats resulted in decreased levels of proinflammatory cytokines (leptin, lL-6, IL-1betha, INF-gamma) and a chemokine (MCP-1), and increased levels of anti-inflammatory adipokine (adiponectin). In addition, treatment decreased the damage and hepatic steatosis generated in the tissue of obese rats. The IMMP exerted an anti-inflammatory effect in obese rats and therefore may be an effective and safe therapeutic alternative in the treatment of metabolic syndrome.

Keywords: Immunomodulator; Inflammation; Metabolic syndrome; Obesity; Peptide

References

  1. Clin Exp Immunol. 1992 Mar;87(3):346-51 - PubMed
  2. Drug Discov Today. 2012 Aug;17(15-16):880-9 - PubMed
  3. Cardiovasc Diabetol. 2013 Mar 18;12:46 - PubMed
  4. Nature. 2008 Jul 24;454(7203):428-35 - PubMed
  5. Nature. 1974 Jan 4;247(5435):11-4 - PubMed
  6. Rev Diabet Stud. 2011 Fall;8(3):355-68 - PubMed
  7. J Clin Biochem Nutr. 2014 Jan;54(1):39-44 - PubMed
  8. Science. 2011 Jun 24;332(6037):1519-23 - PubMed
  9. J Nutr. 2006 Jul;136(7 Suppl):1935S-1939S - PubMed
  10. Immunopharmacol Immunotoxicol. 1990;12(1):123-33 - PubMed
  11. Arq Bras Endocrinol Metabol. 2008 Aug;52(6):968-74 - PubMed
  12. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7265-70 - PubMed
  13. Nature. 2006 Dec 14;444(7121):860-7 - PubMed
  14. Circ Res. 2005 May 13;96(9):939-49 - PubMed
  15. Am J Clin Nutr. 2009 Mar;89(3):985S-990S - PubMed
  16. Diabetol Metab Syndr. 2014 Mar 20;6(1):42 - PubMed
  17. World J Gastroenterol. 2008 Jan 14;14(2):185-92 - PubMed
  18. Heart. 1997 Sep;78(3):273-7 - PubMed
  19. Hepatology. 2010 Feb;51(2):679-89 - PubMed
  20. Endocrinology. 1972 May;90(5):1320-30 - PubMed
  21. FEBS Lett. 2005 Jan 17;579(2):295-301 - PubMed
  22. Nutrients. 2014 Jan 29;6(2):591-604 - PubMed
  23. Int J Mol Sci. 2014 Apr 11;15(4):6184-223 - PubMed
  24. Am J Cardiol. 2006 Jan 16;97(2A):3A-11A - PubMed
  25. J Rheumatol. 2009 Sep;36(9):1885-91 - PubMed
  26. In Vitro Cell Dev Biol Anim. 2014 Aug;50(7):630-9 - PubMed
  27. J Diabetes. 2010 Sep;2(3):180-93 - PubMed
  28. Immunol Res. 1998;17(3):345-68 - PubMed
  29. Eur Cytokine Netw. 2006 Mar;17(1):4-12 - PubMed
  30. J Lipid Res. 2010 Apr;51(4):771-84 - PubMed
  31. Diabetologia. 2013 Nov;56(11):2487-97 - PubMed
  32. Am J Cardiol. 2005 Dec 26;96(12B):13M-18M - PubMed
  33. Eur J Heart Fail. 2014 Jun;16(6):633-8 - PubMed
  34. J Transl Med. 2012 Jul 11;10:145 - PubMed
  35. J Pharmacol Exp Ther. 2008 Jun;325(3):833-40 - PubMed
  36. J Clin Invest. 2010 Jan;120(1):191-202 - PubMed
  37. Endocr Metab Immune Disord Drug Targets. 2013 Sep;13(3):234-9 - PubMed
  38. Horm Metab Res. 2011 Jun;43(7):452-7 - PubMed
  39. Nat Med. 2009 Aug;15(8):846-7 - PubMed
  40. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):629-36 - PubMed
  41. J Endocrinol Invest. 2014 Feb;37(2):175-80 - PubMed
  42. World J Gastroenterol. 2010 Oct 14;16(38):4762-72 - PubMed
  43. Proc West Pharmacol Soc. 2011;54:52-6 - PubMed
  44. Int J Environ Res Public Health. 2014 Apr 14;11(4):4049-65 - PubMed
  45. J Clin Invest. 2003 Dec;112(12):1796-808 - PubMed
  46. J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56 - PubMed

Publication Types